Follow
Shrirang Karve
Shrirang Karve
Sanofi
No verified email
Title
Cited by
Cited by
Year
Folate-targeted nanoparticle delivery of chemo-and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis
ME Werner, S Karve, R Sukumar, ND Cummings, JA Copp, RC Chen, ...
Biomaterials 32 (33), 8548-8554, 2011
2052011
Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery
S Karve, ME Werner, R Sukumar, ND Cummings, JA Copp, EC Wang, ...
Proceedings of the national academy of sciences 109 (21), 8230-8235, 2012
1832012
Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system
F DeRosa, B Guild, S Karve, L Smith, K Love, JR Dorkin, KJ Kauffman, ...
Gene therapy 23 (10), 699-707, 2016
1742016
Folate-targeted polymeric nanoparticle formulation of docetaxel is an effective molecularly targeted radiosensitizer with efficacy dependent on the timing of radiotherapy
ME Werner, JA Copp, S Karve, ND Cummings, R Sukumar, C Li, ...
ACS nano 5 (11), 8990-8998, 2011
1272011
Effect of drug release kinetics on nanoparticle therapeutic efficacy and toxicity
M Sethi, R Sukumar, S Karve, ME Werner, EC Wang, DT Moore, ...
Nanoscale 6 (4), 2321-2327, 2014
932014
Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza
S Chivukula, T Plitnik, T Tibbitts, S Karve, A Dias, D Zhang, R Goldman, ...
npj Vaccines 6 (1), 153, 2021
852021
Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models
KV Kalnin, T Plitnik, M Kishko, J Zhang, D Zhang, A Beauvais, ...
npj Vaccines 6 (1), 61, 2021
792021
Cns delivery of mrna and uses thereof
F DeRosa, M Heartlein, S Karve
US Patent App. 14/521,168, 2015
642015
The pH-dependent association with cancer cells of tunable functionalized lipid vesicles with encapsulated doxorubicin for high cell-kill selectivity
S Karve, A Bandekar, MR Ali, S Sofou
Biomaterials 31 (15), 4409-4416, 2010
582010
Antitumor efficacy following the intracellular and interstitial release of liposomal doxorubicin
A Bandekar, S Karve, MY Chang, Q Mu, J Rotolo, S Sofou
Biomaterials 33 (17), 4345-4352, 2012
562012
Methods for purification of messenger RNA
F DeRosa, A Dias, S Karve, M Heartlein
US Patent 9,850,269, 2017
492017
Heterogeneous Domains and Membrane Permeability in Phosphatidylcholine− Phosphatidic Acid Rigid Vesicles As a Function of pH and Lipid Chain Mismatch
S Karve, G Bajagur Kempegowda, S Sofou
Langmuir 24 (11), 5679-5688, 2008
482008
Methods for purification of messenger RNA
M Heartlein, F DeRosa, A Dias, S Karve
US Patent 9,957,499, 2018
462018
The use of pH-triggered leaky heterogeneities on rigid lipid bilayers to improve intracellular trafficking and therapeutic potential of targeted liposomal immunochemotherapy
S Karve, A Alaouie, Y Zhou, J Rotolo, S Sofou
Biomaterials 30 (30), 6055-6064, 2009
462009
pH-dependent formation of lipid heterogeneities controls surface topography and binding reactivity in functionalized bilayers
GB Kempegowda, S Karve, A Bandekar, A Adhikari, T Khaimchayev, ...
Langmuir 25 (14), 8144-8151, 2009
282009
mRNA therapeutics: beyond vaccine applications
B Bhat, S Karve, DG Anderson
Trends in Molecular Medicine 27 (9), 923-924, 2021
252021
Methods for purification of messenger RNA
F DeRosa, A Dias, S Karve, M Heartlein
US Patent 11,059,841, 2021
232021
Stereochemically enriched compositions for delivery of nucleic acids
F Derosa, S Karve, M Heartlein
US Patent 10,138,213, 2018
232018
Encapsulation of messenger RNA
F DeRosa, S Karve, M Heartlein
US Patent 9,668,980, 2017
222017
Immunogenicity of novel mRNA COVID-19 vaccine MRT5500 in mice and non-human primates
KV Kalnin, T Plitnik, M Kishko, J Zhang, D Zhang, A Beauvais, ...
BioRxiv, 2020.10. 14.337535, 2020
212020
The system can't perform the operation now. Try again later.
Articles 1–20